Pfenex Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Pfenex Inc. - Product Pipeline Review - 2016', provides an overview of the Pfenex Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Pfenex Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Pfenex Inc. - The report provides overview of Pfenex Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Pfenex Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Pfenex Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Pfenex Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pfenex Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pfenex Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Pfenex Inc. Snapshot 5 Pfenex Inc. Overview 5 Key Information 5 Key Facts 5 Pfenex Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Pfenex Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pfenex Inc. - Pipeline Products Glance 12 Pfenex Inc. - Clinical Stage Pipeline Products 12 Phase I Products/Combination Treatment Modalities 12 Pfenex Inc. - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Pfenex Inc. - Drug Profiles 14 ranibizumab biosimilar 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 interferon beta-1b 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Px-563L 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 teriparatide biosimilar 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 certolizumab pegol biosimilar 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 pegaspargase biosimilar 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 pegfilgrastim 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 peginterferon alfa-2a 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 PF-726 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Px-533 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Px-563L Second Generation 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 somatropin 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Pfenex Inc. - Pipeline Analysis 27 Pfenex Inc. - Pipeline Products by Target 27 Pfenex Inc. - Pipeline Products by Route of Administration 28 Pfenex Inc. - Pipeline Products by Molecule Type 29 Pfenex Inc. - Pipeline Products by Mechanism of Action 30 Pfenex Inc. - Recent Pipeline Updates 31 Pfenex Inc. - Dormant Projects 33 Pfenex Inc. - Locations And Subsidiaries 34 Head Office 34 Other Locations & Subsidiaries 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 35 Disclaimer 36
List of Tables
Pfenex Inc., Key Information 5 Pfenex Inc., Key Facts 5 Pfenex Inc. - Pipeline by Indication, 2016 7 Pfenex Inc. - Pipeline by Stage of Development, 2016 8 Pfenex Inc. - Monotherapy Products in Pipeline, 2016 9 Pfenex Inc. - Partnered Products in Pipeline, 2016 10 Pfenex Inc. - Partnered Products/ Combination Treatment Modalities, 2016 11 Pfenex Inc. - Phase I, 2016 12 Pfenex Inc. - Preclinical, 2016 13 Pfenex Inc. - Pipeline by Target, 2016 27 Pfenex Inc. - Pipeline by Route of Administration, 2016 28 Pfenex Inc. - Pipeline by Molecule Type, 2016 29 Pfenex Inc. - Pipeline Products by Mechanism of Action, 2016 30 Pfenex Inc. - Recent Pipeline Updates, 2016 31 Pfenex Inc. - Dormant Developmental Projects,2016 33 Pfenex Inc., Subsidiaries 34
List of Figures
Pfenex Inc. - Pipeline by Top 10 Indication, 2016 7 Pfenex Inc. - Pipeline by Stage of Development, 2016 8 Pfenex Inc. - Monotherapy Products in Pipeline, 2016 9 Pfenex Inc. - Pipeline by Top 10 Target, 2016 27 Pfenex Inc. - Pipeline by Route of Administration, 2016 28 Pfenex Inc. - Pipeline by Molecule Type, 2016 29 Pfenex Inc. - Pipeline Products by Mechanism of Action, 2016 30
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers isRead More...
Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the iRead More...
Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmenRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.